BioNTech (NASDAQ:BNTX) Price Target Raised to $145.00

BioNTech (NASDAQ:BNTX) had its price objective upped by HC Wainwright from $134.00 to $145.00 in a research report released on Thursday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Citigroup reissued a “buy” rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. The Goldman Sachs Group initiated coverage on shares of BioNTech in a research report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 price target for the company. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Finally, Morgan Stanley reduced their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $138.25.

BioNTech Trading Down 1.5%

Shares of NASDAQ:BNTX opened at $108.49 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The stock has a market capitalization of $26.08 billion, a price-to-earnings ratio of -51.66 and a beta of 1.29. The stock’s 50-day simple moving average is $99.26 and its two-hundred day simple moving average is $108.40.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same quarter in the previous year, the company earned $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% on a year-over-year basis. Analysts expect that BioNTech will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently modified their holdings of BNTX. NewEdge Advisors LLC purchased a new stake in shares of BioNTech in the first quarter valued at $167,000. Millennium Management LLC increased its holdings in BioNTech by 252.5% during the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after purchasing an additional 390,360 shares during the last quarter. Banque Transatlantique SA acquired a new stake in BioNTech in the first quarter valued at $80,000. Alyeska Investment Group L.P. grew its stake in BioNTech by 2,769.2% in the first quarter. Alyeska Investment Group L.P. now owns 75,000 shares of the company’s stock worth $6,830,000 after purchasing an additional 72,386 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of BioNTech during the 1st quarter valued at approximately $455,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.